EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Efficacy, safety and predictive biomarker of third‐generation tyrosine kinase inhibitors with azacitidine in myeloid blast phase of chronic myeloid leukemia

Mei Bao, Xiao S Zhang, Zong R Li, Lu Yu iD, Robert Peter Gale, Sha S Zhao, Fang Ye, Cheng C Yan, Xiao J Huang iD, Qian Jiang iD

Cancer · 15.11.2025 · 131 (22)

DOI: 10.1002/cncr.70166 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 06.11.2025. Verfasst von Mei Bao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Ke…. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Azacitidine, Protein Kinase Inhibitors, Blast Crisis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the efficacy, safety, and predictive biomarker of a third‐generation tyrosine kinase inhibitor (3G‐TKI; ponatinib or olverembatinib) combined with azacitidine in chronic myeloid leukemia (CML) in myeloid blast phase.

Methods

We conducted a single‐center, prospective study combining 3G‐TKI with azacitidine in 28‐day cycles. The primary end point was a major hematologic response (MaHR) by cycle 2. The trial is registered in Chinese Clinical Trial Registry (ChiCTR2200055887)

Results

In total, 37 patients were studied. The median follow‐up was 30 months (interquartile range, 24–40 months). Twenty‐five patients achieved a MaHR by cycle 2, 30 returned to chronic phase. Ten patients underwent transplantation. The patients who underwent transplantation had higher 3‐year probability of survival compared with nontransplanted patients (50%; [95% confidence interval (CI), 9%–37%] versus 18% [95% CI, 3%–33%]; p = .01). The regimen was well tolerated. In adjusted logistic/Cox regression analyses, KRAS mutation was significantly associated with a lower MaHR rate (odds ratio, 0.1; 95% CI, 0–0.8; p = .03), worse progression‐free survival (PFS; hazard ratio [HR], 3.1; 95% CI, 1.1–8.6; p = .04), and worse survival (HR, 8.2; 95% CI, 2.5–26.8; p < .001); PTPN11 mutation was associated with worse PFS (HR, 5.1; 95% CI, 1.2–22.2; p = 0.03) and worse survival (HR, 9.6; 95% CI, 2.2–41.5; p = .002); and increasing numbers of non‐ ABL1 mutations were associated with worse PFS (HR, 1.2; 95% CI, 1.0–1.3; p = .04). Transcriptomic analysis revealed that patients who did not achieve a MaHR experienced activation of cancer‐, metabolism‐, oxidative phosphorylation‐related pathways. The KRAS signaling pathway was significantly activated in patients who lost MaHR during treatment.

Conclusions

3G‐TKI with azacitidine is an effective and safe therapy providing more chance to receive a transplantation for CML in myeloid blast phase. Potential biomarkers associated with outcomes were identified.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveAzacitidineProtein Kinase InhibitorsBlast CrisisAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedAdultProspective StudiesAgedImidazolesPyridazinesBiomarkers, TumorTreatment OutcomeMutationTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

azacitidinechronic myeloid leukemiamyeloid blast phaseolverembatinibponatinib

Substanzen

AzacitidineProtein Kinase InhibitorsponatinibImidazolesPyridazinesBiomarkers, TumorTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, Chin…
  • Department of Immunology and Inflammation, Center for Hematology Research, Imperial College London, London, UK.
  • Peking University People's Hospital, Qingdao, China.
  • Chuiyangliu Hospital affiliated with Tsinghua University, Beijing, China.
  • Tianjin Kingmed Diagnostics Laboratory Company Ltd., Tianjin, China.

ORCID-Profile: Lu Yu, Xiao J Huang, Qian Jiang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Bao, M., Zhang, X. S., Li, Z. R., Yu, L., Gale, R. P., Zhao, S. S., Ye, F., Yan, C. C., Huang, X. J., & Jiang, Q. (2025). Efficacy, safety and predictive biomarker of third‐generation tyrosine kinase inhibitors with azacitidine in myeloid blast phase of chronic myeloid leukemia. Cancer, 131(22). https://doi.org/10.1002/cncr.70166

Vancouver

Bao M, Zhang XS, Li ZR, Yu L, Gale RP, Zhao SS, et al. Efficacy, safety and predictive biomarker of third‐generation tyrosine kinase inhibitors with azacitidine in myeloid blast phase of chronic myeloid leukemia. Cancer. 2025;131(22). doi:10.1002/cncr.70166

BibTeX
@article{Bao2025,
  author = {Bao, Mei and Zhang, Xiao S and Li, Zong R and Yu, Lu and Gale, Robert Peter and Zhao, Sha S and Ye, Fang and Yan, Cheng C and Huang, Xiao J and Jiang, Qian},
  title = {Efficacy, safety and predictive biomarker of third‐generation tyrosine kinase inhibitors with azacitidine in myeloid blast phase of chronic myeloid leukemia},
  journal = {Cancer},
  year = {2025},
  volume = {131},
  number = {22},
  doi = {10.1002/cncr.70166}
}
Kostenlos starten →